This study is a prospective, multicentre, randomized, open-label, blinded-endpoint clinical trial to evaluate the efficacy and safety of Yangxinshi tablets in the treatment of patients with chronic coronary syndrome (CCS).
age 18-75 years;
CCS patients in stable condition and clearly diagnosed by coronary artery imaging (at least one vessel stenosis ≥ 50%): stable angina, ischaemic cardiomyopathy, asymptomatic or stable symptoms, occult coronary heart disease, acute coronary syndrome (ACS), or >3 months after coronary revascularization;
moderately to severely limited exercise tolerance: the maximum 6MWD is < 450 m, or the metabolic equivalent (MET) as measured by treadmill cardiopulmonary exercise testing is < 5 METs;
voluntary participation and signing of informed consent.
absolute or relative contraindications for the treadmill cardiopulmonary exercise test or 6-minute walk test (6MWT);
serious primary diseases, mental diseases, or malignant tumours that affect lifespan;
pregnancy, intended or suspected pregnancy, miscarriage, breastfeeding, or delivery in the last 6 months;
subjects not suitable for this study in the opinion of the researchers, such as subjects who are participating in other drug clinical trials or intervention studies.